Evertec (NYSE:EVTC) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 16.67 percent decrease over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $160.57 million which beat the analyst consensus estimate of $151.79 million by 5.78 percent. This is a 7.66 percent increase over sales of $149.15 million the same period last year.
Regeneron’s Dupixent Approved By FDA As First And Only Treatment Indicated For Prurigo Nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
About 75,000 adults in the U.S. living with prurigo nodularis are most in need of
